Kite Pharma, Inc. (NASDAQ:KITE).
On August 30, 2016 BTIG Research started coverage by announcing an initial rating of “Neutral”. Barclays starting coverage on KITE setting a rating of “Equal-weight” and a price target of $58.00.
On June 2 analysts at Raymond James started covering the stock giving it an initial rating of “Outperform”. On March 1 Jefferies made no change to the company rating of “Buy” and lowered the price expectation from $92.00 to $75.00.
March 1 investment analysts at Stifel Nicolaus left the stock rating at “Buy” but lowered the price target to $63.00 from $98.00.
The company is up from yesterday’s close of $54.98. Shares of the company are trading at $59.59 which is marginally higher than $58.24, the stock’s 50 day moving average and just a bit higher than the 200 day moving average of $51.55. The 50 day moving average went up $2.05 or +3.53% and the 200 day average went up by +16.96%.
In the latest earnings report the EPS was $-3.73 and is expected to be $-5.82 for the current year with 49,596,000 shares outstanding. Analysts expect next quarter’s EPS to be $-1.96 and the next full year EPS is projected to be $-6.39.
Investors are more bullish lately if you watch the change in short interest. The firm experienced a fall in short interest of -0.05% between August 31, 2016 and September 15, 2016. Short interest fell from 6,458,295 to 6,130,314 over that timeframe. Days to cover decreased -0.9 to 8.5 and the short interest percentage is 0.12% as of September 15.